AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.
